JNJ-64179375 0.3 mg/kg

DRUG2 trials

Sponsors

Janssen Research & Development, LLC

Conditions

HealthyVTE Prophylaxis With Anticoagulation After Total Knee Replacement Surgery

Phase 1

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of JNJ-64179375 in Healthy Japanese Participants

CompletedNCT03080987

Janssen Research & Development, LLCHealthy

Start: 2017-06-27End: 2018-06-25Updated: 2025-02-03

Phase 2

A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery

CompletedNCT03251482

Janssen Research & Development, LLCVTE Prophylaxis With Anticoagulation After Total Knee Replacement Surgery

Start: 2017-11-13End: 2018-11-05Updated: 2019-11-25